The FDA and other Health Authorities worldwide have focused their attention on data integrity, considering data integrity to be a significant risk to public safety. This is evident in the number of Warning Letter observations and related Import Alerts issued in the last 5-7 years. Data integrity is not a new topic, however, but is a part of the GMPs. Often, companies attempt to address data integrity issues procedurally and by conducting numerous training programs. These tend to be ineffective as data integrity issues are often rooted in a company's culture and may be very difficult to address.
Topics covered in this seminar include the concepts of data integrity Part 11 compliance, risk management, and quality management systems. Through an extensive case study, attendees will work through cultural challenges that contribute to data integrity issues and make change difficult. Many of the examples provided during the seminar will come from the instructor's experience finding data integrity issues during routine supplier audits, and Warning Letter remediation activities that involved data integrity observations. This includes how to conduct a data integrity investigation and targeting the right group for training / discipline.Learning Objectives: